How Early is Too Early? Valuing and De-Risking Preclinical Opportunities

3:15 PM - 4:15 PM, Tuesday, June 4,2019 ・ 109AB, Level 100
Valuing early-stage opportunities is challenging. Modeling will often provide a false sense of accuracy but relying on comparable transactions is more art than science. With a long lead time to launch, even the most robust estimates can ultimately prove inaccurate. This interactive panel will feature venture capital investors and senior pharma and biotech executives who lead early-stage transactions as they discuss their approaches to valuing opportunities, and offer key learnings from both successful and not-so-successful experiences.
Speakers
photo
Associate Vice President and Head, Boston Innovation Hub Business Development & Licensing
Merck
photo
Head BD&L MS, AD, OPN, Platforms
Biogen
photo
Managing Partner
TVM Life Science Management Inc
photo
Partner
Wilson Sonsini Goodrich and Rosati, P.C.